Biofield Signs Master Agreement
PHILADELPHIA (July 30, 2007) - Share prices for the Biofield Corp. (OTCBB: BZET) jumped 41 percent today, after it announced its recent master license agreement with MacKay Group Limited to market its breast cancer diagnostic system. According to the statement, this agreement grants the MacKay Group an "exclusive, sub-licensable royalty-bearing license" to distribute, manufacture, develop, and commercialize Biofield's breast cancer technology on the worldwide market. In return, the MacKay Group will pay Biofield a number of royalties based on the gross receipts received by MacKay Group and its affiliates, along with a payment of $1 million for licensing fees. This…